[ad_1]
New York, USA, July 26, 2021 (Global News Agency)- Overview of the 3D Bioprinting Market
According to an extensive research report published by Market Research Future (MRFR), “3D bioprinting market Information by technical material, application, end user and region-forecast to 2028“The market is expected to reach 4.3 billion US dollars by 2028, with a compound annual growth rate of 15.5%.
Market scope:
In the 3D bioprinting market, the widespread use of 3D bioprinting in the cosmetics sector is expected to play a vital role in defining market growth potential. Bioprinting devices, such as organs on a chip, can be used to study 3D human processes outside the body. 3D bioprinting is also increasingly used for pharmaceutical advancement and drug verification. It will be used in clinical situations in the future. With the advancement of bioprinting, it will be able to use the patient’s own cells to 3D print skin and bone grafts, organ patches, and even entire replacement organs. 3D bioprinting may be a solution to the global organ shortage and the increasing reluctance to test new cosmetics, chemicals and drugs on animals.
Market drivers:
By 2028, the driving force of the bio 3D printing market is mainly the growth in the demand for organ transplants. Increasing public and private investment in 3D bioprinting to expand its scope of influence is expected to promote market growth. In addition, given the cost of 3D bioprinting products, the industry is expected to develop during the forecast period. The widespread use of 3D bioprinting in the cosmetics industry is expected to provide several growth opportunities for major players.
Get a free sample PDF manual@ https://www.marketresearchfuture.com/sample_request/869
Competitive landscape:
Outstanding companies in the bio 3D printing market are
- Organovo Holdings Inc. (United States)
- Ruijia Biotechnology Co., Ltd. (China)
- FUJIFILM Your Automation Corporation (United States)
-
The full story on Benzinga.com
[ad_2]
Source link
